Literature DB >> 15845446

Gene modification strategies to induce tumor immunity.

Amanda Murphy1, Jennifer A Westwood, Michele W L Teng, Maria Moeller, Phillip K Darcy, Michael H Kershaw.   

Abstract

The immune system provides an attractive option for use in cancer therapy. Our increasing understanding of the molecular events important in the generation of an effective immune response presents us with the opportunity to manipulate key genes to boost the immune response against cancer. Genetic modification is being employed to enhance a range of immune processes including antigen presentation, activation of specific T cells, and localization of immune effectors to tumors. In this review, we describe how many diverse cell types, including dendritic cells, T cells, and tumor cells, are being modified with a variety of genes, including those encoding antigens, cytokines, and chemokines, in order to enhance tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15845446     DOI: 10.1016/j.immuni.2005.03.007

Source DB:  PubMed          Journal:  Immunity        ISSN: 1074-7613            Impact factor:   31.745


  15 in total

1.  Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2.

Authors:  Richard A Morgan; James C Yang; Mio Kitano; Mark E Dudley; Carolyn M Laurencot; Steven A Rosenberg
Journal:  Mol Ther       Date:  2010-02-23       Impact factor: 11.454

2.  Proteasomal chymotrypsin-like peptidase activity is required for essential functions of human monocyte-derived dendritic cells.

Authors:  Cord Naujokat; Carsten Berges; Alexandra Höh; Hubert Wieczorek; Dominik Fuchs; Jörg Ovens; Marion Miltz; Mahmoud Sadeghi; Gerhard Opelz; Volker Daniel
Journal:  Immunology       Date:  2006-11-03       Impact factor: 7.397

Review 3.  Designer blood: creating hematopoietic lineages from embryonic stem cells.

Authors:  Abby L Olsen; David L Stachura; Mitchell J Weiss
Journal:  Blood       Date:  2005-10-27       Impact factor: 22.113

4.  Considerations for the clinical application of chimeric antigen receptor T cells: observations from a recombinant DNA Advisory Committee Symposium held June 15, 2010.

Authors:  Hildegund C J Ertl; John Zaia; Steven A Rosenberg; Carl H June; Gianpietro Dotti; Jeffrey Kahn; Laurence J N Cooper; Jacqueline Corrigan-Curay; Scott E Strome
Journal:  Cancer Res       Date:  2011-05-01       Impact factor: 12.701

Review 5.  Induction/engineering, detection, selection, and expansion of clinical-grade human antigen-specific CD8 cytotoxic T cell clones for adoptive immunotherapy.

Authors:  Matjaz Jeras; Irena Bricl; Robert Zorec; Urban Svajger
Journal:  J Biomed Biotechnol       Date:  2010-03-10

Review 6.  Adoptive cell transfer: a clinical path to effective cancer immunotherapy.

Authors:  Steven A Rosenberg; Nicholas P Restifo; James C Yang; Richard A Morgan; Mark E Dudley
Journal:  Nat Rev Cancer       Date:  2008-04       Impact factor: 60.716

Review 7.  Optimal management of metastatic melanoma: current strategies and future directions.

Authors:  Marta Batus; Salman Waheed; Carl Ruby; Lindsay Petersen; Steven D Bines; Howard L Kaufman
Journal:  Am J Clin Dermatol       Date:  2013-06       Impact factor: 7.403

8.  Efficient human hematopoietic cell transduction using RD114- and GALV-pseudotyped retroviral vectors produced in suspension and serum-free media.

Authors:  Karim Ghani; Xiuyan Wang; Pedro Otavio de Campos-Lima; Malgorzata Olszewska; Amine Kamen; Isabelle Rivière; Manuel Caruso
Journal:  Hum Gene Ther       Date:  2009-09       Impact factor: 5.695

9.  A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity.

Authors:  Yangbing Zhao; Qiong J Wang; Shicheng Yang; James N Kochenderfer; Zhili Zheng; Xiaosong Zhong; Michel Sadelain; Zelig Eshhar; Steven A Rosenberg; Richard A Morgan
Journal:  J Immunol       Date:  2009-11-01       Impact factor: 5.422

Review 10.  Focus on adoptive T cell transfer trials in melanoma.

Authors:  Liat Hershkovitz; Jacob Schachter; Avraham J Treves; Michal J Besser
Journal:  Clin Dev Immunol       Date:  2010-12-26
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.